ANTI-LR11 MONOCLONAL ANTIBODY HAVING NEUTRALIZING ACTIVITY AND PHARMACEUTICAL COMPRISING THE SAME

摘要

PROBLEM TO BE SOLVED: To provide a novel monoclonal antibody that specifically binds to LR11 and has excellent neutralizing activity, and a pharmaceutical agent comprising the same for preventing and/or treating malignant tumors.SOLUTION: The invention provides an anti-LR11 monoclonal antibody having at least one amino acid sequence selected from the group of specified sequences as the complementarity determining region (CDR), which the antibody can: (a) recognizes LR11; (b) specifically binds to a protein comprising the amino acid sequence of LR11 Vps10p domain; and (c) in a cell adhesion assay, significantly inhibits the cell adhesion promoted by a protein comprising an amino acid sequence of human LR11 Vps10p domain. Also provided is a pharmaceutical agent comprising the anti-LR11 monoclonal antibody for preventing and/or treating malignant tumors.